Valuation: Thiogenesis Therapeutics, Corp.

Market Cap 34.99M 24.74M 21.99M 20.38M 18.54M 2.35B 35.55M 245M 96.05M 1.23B 92.83M 90.86M 3.91B P/E 2024
-8.65x
P/E 2025 -4.25x
Enterprise Value 33.37M 23.59M 20.97M 19.44M 17.69M 2.24B 33.91M 234M 91.61M 1.17B 88.55M 86.66M 3.73B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
85.84%
Yield 2024 *
-
Yield 2025 -
1 day-1.96%
1 week-5.66%
Current month+2.04%
3 months-12.28%
6 months-18.03%
Current year-23.08%
1 week 0.5
Extreme 0.5
0.55
1 month 0.48
Extreme 0.48
0.58
Current year 0.44
Extreme 0.44
0.66
1 year 0.44
Extreme 0.44
0.81
3 years 0.44
Extreme 0.44
1.06
5 years 0.38
Extreme 0.375
1.06
10 years 0.38
Extreme 0.375
1.06
Manager TitleAgeSince
Chief Executive Officer 75 2022-03-30
Chief Executive Officer 60 -
Director TitleAgeSince
Chairman 73 2022-03-30
Director/Board Member 75 2022-03-30
Director/Board Member 60 2018-05-02
Date Insider Type Main position Quantity % Market Cap. Importance
9/29/26 Buy

Chief Financial Officer

50,000 0.0714%
9/22/26
Rosalind Advisors, Inc.
BuyCompany 249,500 0.3565%
9/17/26 Option

Director

200,000 0.2858%
Change 5-day change 1-year change 3-year change Capi.($)
-1.96%-5.66%-26.47%-36.71% 24.74M
-6.60%-8.56%+49.38%+63.51% 65B
+0.03%+5.56%+9.10%+69.05% 51.2B
-4.09%-0.11%+2.22%+53.15% 51.19B
-1.53%+2.70%+30.48%+34.12% 43.93B
-1.34%+4.12%+16.64%+115.13% 41.96B
-5.97%-6.22%+228.95%+454.22% 38.14B
+6.53%+8.02%+16.40%+53.41% 33.24B
-0.90%-10.49%+37.09%-3.70% 25.2B
-1.07%+2.33%+19.43%+9.98% 22.5B
Average -1.69%-0.88%+38.32%+81.22% 37.24B
Weighted average by Cap. -2.20%-0.50%+44.24%+96.53%

Financials

2024 2025
Net sales - -
Net income -3.15M -2.22M -1.98M -1.83M -1.67M -211M -3.2M -22.02M -8.64M -110M -8.35M -8.17M -351M -7.43M -5.25M -4.67M -4.33M -3.94M -498M -7.55M -51.99M -20.38M -260M -19.7M -19.28M -829M
Net Debt -3.85M -2.72M -2.42M -2.24M -2.04M -258M -3.91M -26.94M -10.56M -135M -10.21M -9.99M -429M -1.62M -1.14M -1.02M -941K -856K -108M -1.64M -11.31M -4.44M -56.58M -4.29M -4.2M -180M
Projected Income Statement - Annual - Thiogenesis Therapeutics, Corp.
Logo Thiogenesis Therapeutics, Corp.
Thiogenesis Therapeutics, Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is developing sulfur-containing prodrugs that act as precursors with the potential to treat serious pediatric diseases with unmet medical needs. Its lead compound, TTI-0102, is a disulfide, made up of two thiols that lead to two independent cysteamine molecules. Cysteamine is a thiol that has been rigorously studied and tested. TTI-0102 has been developed to address the obstacles facing previous thiol-based drugs, their short half-lives and side effects. As a prodrug, TTI-0102 is metabolized into cysteamine molecules after it is ingested. The metabolic process acts as a gating mechanism that eliminates the spike in the immediate release of cysteamine that is commonly linked to GI side effects. TTI-0102’s initial applications are for mitochondrial encephalopathy, lactic acidosis and stroke-like episodes, Leigh syndrome, Rett syndrome and pediatric Nonalcoholic steatohepatitis.
Employees
-
Date Price Change Volume
26-10-16 $0.5000 -1.96% 16,500
26-10-15 $0.5100 +2.00% 10,000
26-10-14 $0.5000 -9.09% 19,000
26-10-13 $0.5500 +3.77% 16,752

Net sales - Rate of surprise

Rate of surprise - Net sales - Annual - Thiogenesis Therapeutics, Corp.